NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
Last week, six companies reported financial results, Ascendis Pharma announced 2-year results from a post-hoc analysis of the company’s phase 3 PaTHway Trial, there was a small insider buy in Pila Pharma as well as a new price target by Danske Bank on Zealand Pharma.
9 of the 22 Danish healthcare companies had a positive share price development the past week and 8 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 170% return and Prostatype Genomics was the best Nordic healthcare investment last week.
Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.
DANISH COMPANY NEWS
Acarix AB (publ) publishes Interim Report, January – March 2024 (Link)
Acarix CPT III Code Removed from United Healthcare Medicare Advantage Noncovered List (Link)
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism (Link)
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial (Link)